Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Aelan Cell Technologies : Names King Jordan, Ph.D. to Its Scientific Advisory Board

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13/2016 | 01:30pm EDT

SAN FRANCISCO, CA--(Marketwired - Jan 13, 2016) - Aelan Cell Technologies announced today the appointment of King Jordan, Ph.D. to its Scientific Advisory Board. Dr. Jordan is an Associate Professor in the School of Biology and Director of the Bioinformatics Graduate Program at the Georgia Institute of Technology.

Dr. Jordan combines academic expertise in biology and genetics with 20 years of experience in bioinformatics. His work entails the development and application of computational tools for the analysis of genome sequences, along with various 'omics' functional analyses, and he has published more than 100 papers in scientific journals such as Nature, Proceedings of the National Academy of Sciences, Nucleic Acids Research, and Bioinformatics. Additionally, Dr. Jordan has been awarded research grants from the National Institutes of Health (NIH), the National Science Foundation, the Centers for Disease Control and Prevention, the Georgia Research Alliance, and the Alfred P. Sloan Foundation.

"Dr. Jordan is a national expert in bioinformatics, and he will be an invaluable asset to our team at Aelan," said Victoria Lunyak, Ph.D., the President and CEO of Aelan. "We have worked with Dr. Jordan on research projects in the past, and we're looking forward to continuing to work with him as Aelan grows."

"Dr. Jordan brings an important scientific background in bioinformatics, as well as genomics," added Chester Aldridge, Chairman of Aelan's Board of Directors and CEO of U.S. Equity Holdings. "He also is an expert in big data analysis, something that will be critical for Aelan as the company continues to develop treatments and technologies." 

At the Georgia Institute of Technology, Dr. Jordan's laboratory conducts research in bioinformatics and genomics, focusing on the analysis of large data sets in hopes of furthering the scientific understanding of the molecular and genetic determinants of human health.

"I am very excited to join Aelan Cell Technologies as a member of its Scientific Advisory Board," Dr. Jordan said. "In past experiences working with Aelan, I have been very impressed, and I look forward to helping the company continue to expand its research and development capabilities over the coming months and years."

Dr. Jordan received a B.S. in Biology from the University of Colorado and earned his Ph.D. in Genetics from the University of Georgia, after which he trained at the National Center for Biotechnology Information at the NIH, widely considered the world's leading bioinformatics institute. Dr. Jordan has also worked to develop bioinformatics and genomics capacity outside the United States, particularly in Latin America. In 2012, he was named a Fulbright Fellow to Colombia, and he is the Co-Founder and Director of the PanAmerican Bioinformatics Institute. Additionally, Dr. Jordan serves as an external scientific advisor to BIOS -- the Colombian National Center of Bioinformatics.

In addition to his academic work, Dr. Jordan consults with industry partners to help provide custom solutions to their bioinformatics challenges through his company Genomic Informatics Consulting.

About Aelan Cell Technologies:
Aelan Cell Technologies is a San Francisco startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity. With a growing intellectual property portfolio of disruptive technologies and medical tools, Aelan has assembled an experienced team -- bringing together scientific and business expertise -- to successfully lead its products through each phase of development.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2949135


© Marketwired 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
10:54pInstacart, Amazon workers strike as labor unrest grows during coronavirus crisis
RE
10:51pSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS BDX, SBT, TUP, TVTY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
10:51pSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS HPQ, JELD, OXY, WWE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
10:51pSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS SIX, SSL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
10:51pSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
10:51pSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS ALGN, TLRY, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
10:48pOUROFINO ÚDE ANIMAL PARTICIPAÇ&OTI : Notice to the Market - Covid-19 and Retention of dividends
PU
10:40pTalon Metals Reports Results for the Year Ended December 31, 2019
NE
10:38pCSM : SPH Notice – Lindsay Investment Trust
PU
10:37pTENCENT : backed online education firm Yuanfudao raises $1 billion in new round
RE
Latest news "Companies"